Charles A. Nicolette

Chief Executive Officer at CoImmune, Inc.

Charles A. Nicolette

Charles A. Nicolette

Chief Executive Officer at CoImmune, Inc.

Overview
Career Highlights

CoImmune, Inc.

RelSci Relationships

811

Number of Boards

1

Birthday

1963

Age

58

Relationships
RelSci Relationships are individuals Charles A. Nicolette likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Gurnet Point Capital LLC

Relationship likelihood: Strong

General Manager-Sanofi BioSurgery Business Unit at Genzyme Corp.

Relationship likelihood: Strong

Treasurer at The Boston Consulting Group International, Inc.

Relationship likelihood: Strong

Chief Executive Officer & President at Millendo Therapeutics, Inc.

Relationship likelihood: Strong

Chief Executive Officer & Director at Novadip Biosciences SA

Relationship likelihood: Strong

Senior Vice President & General Manager (Hybridon Specialty Products) at Idera Pharmaceuticals, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Antiva Biosciences, Inc.

Relationship likelihood: Average

Chief Financial Officer at Werewolf Therapeutics, Inc.

Relationship likelihood: Average

Former Vice President, Finance & Chief Accounting Officer at Argos Therapeutics, Inc.

Relationship likelihood: Average

Chief Financial & Accounting Officer at Allena Pharmaceuticals, Inc.

Relationship likelihood: Average

Paths to Charles A. Nicolette
Potential Connections via
Relationship Science
You
Charles A. Nicolette
Chief Executive Officer at CoImmune, Inc.
Education
Ph.D Biochemistry, Cellular & Developmental Biology

The State University of New York is the largest comprehensive university system in the United States, educating approximately 468,000 students in more than 7,500 degree and certificate programs, and more than 1.8 million NYS citizens in professional development and personal enrichment programs, on 64 college and university campuses. There are nearly 3 million SUNY alumni worldwide.

Career History
Chief Executive Officer
Current

CoImmune, Inc. engages in manufacture and development of cell-based therapeutics. It offers warehouse management, processing suites, logistics, research labs, and qualification and validation. The company was founded in February 2019 and is headquartered in Durham, NC.

Director of Antigen Discovery
Tenure Unconfirmed

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Chief Scientific Officer & Vice President, Research & Development
2003 - 2018

Argos Therapeutics, Inc. is a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and is headquartered in Durham, NC.

Transactions
Details Hidden

Argos Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Argos Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Argos Therapeutics, Inc. raised money in a private placement transaction

Investments
Details Hidden

Argos Therapeutics, Inc. is a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and is headquartered in Durham, NC.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Charles A. Nicolette. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Charles A. Nicolette's profile does not indicate a business or promotional relationship of any kind between RelSci and Charles A. Nicolette.